Toggle light / dark theme

There might be billions, even trillions, of rogue planets in the Milky Way. Could they support life? How can we find out?


The search for potentially habitable planets is focused on exoplanets—planets orbiting other stars—for good reason. The only planet we know of with life is Earth and sunlight fuels life here. But some estimates say there are many more rogue planets roaming through space, not bound to or warmed by any star.

Could some of them support life?

About six years ago, the CEO of Toyota Research Institute published a seminal paper about whether a Cambrian explosion was coming for robotics. The term “Cambrian explosion” refers to an important event approximately half a billion years ago in which there was a rapid expansion of different forms of life on earth. There are parallels with the field of robotics as modern technological advancements are fueling an analogous explosion in the diversification and applicability of robots. Today, we’re seeing this Cambrian explosion of robotics unfolding, and consequently, many distinct patterns are emerging. I’ll outline the top three trends that are rapidly evolving in the robotics space and that are most likely to dominate for years to come.

1. The Democratization Of AI And The Convergence Of Technologies.

The birth and proliferation of AI-powered robots are happening because of the democratization of AI. For example, open-source machine learning frameworks are now broadly accessible; AI algorithms are now in the open domain in cloud-based repositories like GitHub; and influential publications on deep learning from top schools can now be downloaded. We now have access to more computing power (e.g., Nvidia GPUs, Omniverse, etc.), data, cloud-computing platforms (e.g., Amazon AWS), new hardware and advanced engineering. Many robotics startup companies are capitalizing on this “super evolution” of technology to build more intelligent and more capable machines.

And, depending on how further studies progress, it could be implemented via gene therapy.

Early-stage pancreatic cancer has a ‘reset button’

“These findings open up the possibility of designing a new gene therapy or drug because now we can convert cancerous cells back into their normal state,” said Professor Bumsoo Han of Purdue’s mechanical engineering, who is also the program leader for the university’s Center for Cancer Research, in a blog post shared on the university’s official website. Han has also received a courtesy appointment in biomedical engineering, according to the post. The new time machine (speaking figuratively) from Han’s lab is a lifelike reproduction of a specific structure of the pancreas, called the acinus, which secretes and produces digestive enzymes into the small intestine. When pancreatic cancer strikes, it typically comes from chronic inflammation, which is caused by a mutation that tricks the digestive enzymes to begin digesting the pancreas itself. This is bad.

Brains aren’t the easiest of organs to study, what with their delicate wiring and subtle whispering of neurotransmitter messages. Now, this research could be made a little easier, as we’ve learned we can swap some critical chemical systems with the host animal being none the wiser.

In a proof-of-concept study run by a team of US researchers, the microscopic worm Caenorhabditis elegans was genetically gifted pieces of a nervous system taken from a radically different creature – a curious freshwater organism known as Hydra.

The swap wasn’t unlike teaching a specific brain circuit a foreign language, and finding it performs its job just as well as before.

Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer.


Scientists have unveiled new maps of the protein networks underlying different types of cancer, offering a potentially clearer way to see what’s driving the disease and to find therapeutic targets.

Sequencing the genetic information of tumors can provide a trove of data about the mutations contained in those cancer cells. Some of those mutations help doctors figure out the best way to treat a patient, but others remain more of a mystery than a clear instruction manual. Many are exceedingly rare, or there are so many mutations it’s not clear what’s fueling the cancer.